Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 588
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

588 results for “placebo” Back to intelligence hub

Search results

Page 17 of 25
  1. Placebo capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Pain Threshold

    phase 2 small molecule completed

    1 trial
  2. Placebo de macitentan 10 mg, MACITENTAN

    Pari Pharma GmbH

    Inoperable Chronic thromboembolic pulmonary hyperTension, Pneumology

    phase 2 small molecule active

    1 trial
  3. Placebo for ABBV-142

    AbbVie Deutschland GmbH & Co. KG

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial
  4. Placebo for ACP-204 capsules

    Lacuna Pharma Pty Ltd

    Lewy Body Dementia Psychosis (LBDP)

    phase 2 small molecule active

    1 trial
  5. Placebo for AMG 133, AMG 133

    Amgen

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial
  6. Placebo for AMG 451, Rocatinlimab

    Amgen

    Moderate-to-severe Asthma

    phase 2 small molecule active

    1 trial
  7. Placebo for AZD4144, AZD4144

    AstraZeneca AB

    Sepsis-associated acute kidney injury (AKI)

    phase 2 small molecule active

    1 trial
  8. Placebo for AZD5148, AZD5148

    AstraZeneca AB

    Recurrence of Clostridioides difficile Infection

    phase 2 small molecule active

    1 trial
  9. Placebo for GSK5784283.

    GlaxoSmithKline

    Asthma

    phase 2 small molecule active

    1 trial
  10. Placebo for JNJ-95597528, JNJ-95597528

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial
  11. Placebo for KER-012, cibotercept

    Keros Therapeutics

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial
  12. Placebo for LAD603, LAD603

    Almirall, S.A.

    Alopecia areata

    phase 2 small molecule active

    1 trial
  13. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Radiographic axial spondyloarthritis (as known as ankylosing spondylitis)

    phase 2 small molecule active

    1 trial
  14. Placebo for ML-007C-MA bilayer tablet

    MapLight Therapeutics

    Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

    phase 2 small molecule active

    1 trial
  15. Placebo for SPT-300

    Seaport Therapeutics

    Major Depressive Disorder (MDD), with or without Anxious Distress

    phase 2 small molecule active

    1 trial
  16. Placebo for bms-986435-01

    Bristol-Myers Squibb Australia Pty Ltd

    Heart failure with preserved ejection fraction (HFpEF)

    phase 2 small molecule active

    1 trial
  17. Placebo matching BI 764198, BI 764198

    Boehringer Ingelheim

    Proteinuric kidney diseases

    phase 2 small molecule active

    1 trial
  18. Placebo of IPN10200, IPN10200

    Ipsen

    Cervical Dystonia

    phase 2 small molecule active

    1 trial
  19. Placebo of NAL, NACYSTELYN

    Laboratoire HRA Pharma

    Obstructive Sleep Apnea

    phase 2 small molecule active

    1 trial
  20. Placebo oral capsule

    United Therapeutics Europe Ltd

    Osteoarthritis, Knee

    phase 2 small molecule completed

    1 trial
  21. Placebo session 1, Aprepitant session 2

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial
  22. Placebo to AVTX-009, AVTX-009

    Avalo Therapeutics

    Hidradenitis suppurativa (HS)

    phase 2 small molecule active

    1 trial
  23. Placebo to BAY 3401016, BAY 3401016

    Bayer AG

    Alport Syndrome, Chronic kidney disease

    phase 2 small molecule active

    1 trial
  24. Placebo to BI 765423, BI 765423

    Boehringer Ingelheim

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.